|
|
- Penicillin allergy that persisted after 66 years: case report
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Anukam, E; Zhu, J.
Pages: e25 - e25
Abstract: The most common documented allergy is due to penicillin use, and penicillin allergy is often diagnosed early in childhood. However, fewer than 1% of the approximately 10% of the population with reported penicillin allergy have a true allergy. Antimicrobial stewardship programmes have employed pharmacist-led protocols to rechallenge patients with a documented history of penicillin allergy. There are published data to suggest that patients with a history of penicillin allergy can be successfully rechallenged and desensitised. We report a case of a 74-year-old woman with a documented childhood history of penicillin allergy who was rechallenged with amoxicillin/clavulanate (Augmentin) in the hospital during admission. She was given one trial dose of amoxicillin/clavulanate for the treatment of urinary tract infection to cover organisms detected in the urine culture. Amoxicillin/clavulanate was determined to be the most suitable antibiotic for empirical treatment. Given a documented history of penicillin allergy from over 60 years ago, the likelihood of reactivity was suspected to be low to none. The patient, however, developed an allergic reaction after the one-time oral amoxicillin/clavulanate 875/125 mg dose trial.
PubDate: 2023-08-23T00:45:27-07:00
DOI: 10.1136/ejhpharm-2022-003293
Issue No: Vol. 30, No. 5 (2023)
- Rare complication of doxorubicin-induced complete heart block in a patient
with Hodgkins lymphoma: a case report-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Mahadevappa, M; Pura Krishnamurthy, K, Attri, L. K, Chandrappa, Y, Kulkarni, P.
Pages: e26 - e26
Abstract: Anthracyclines are associated with cardiotoxic manifestations that are mainly dose-dependent, with onset varying from a few days to many years after stopping treatment. Frequent monitoring for toxic manifestations, early detection, cessation of anthracycline use and appropriate treatment is the key to preventing morbidity and mortality. Complete heart block with doxorubicin use in Hodgkin’s lymphoma is rarely reported, and is a severe toxic manifestation necessitating withdrawal or changing of regimen to etoposide + bleomycin + vinblastine + dacarbazine (EBVD), as in this case.
PubDate: 2023-08-23T00:45:27-07:00
DOI: 10.1136/ejhpharm-2022-003417
Issue No: Vol. 30, No. 5 (2023)
- COVID-19 vaccine triggered autoimmune hepatitis: case report
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Mathew, M; John, S. B, Sebastian, J, Ravi, M. D.
Pages: e27 - e27
Abstract: Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory autoimmune disease in which one’s own immune system attacks healthy, normal hepatic cells. The exact cause of AIH is unknown; however, the combination of genetic, environmental (eg, drugs and natural infection) and immunological factors may lead to AIH. AIH may also be potentiated with the use of vaccines: this case reports one such event following immunisation, along with 1 year of follow-up. A female patient in her late 20s presented to the hospital with yellowish discolouration of eyes, urine and stools. Her medical history revealed that she had been vaccinated with the first dose of a COVID-19 vaccine 10 days earlier. She had a history of asymptomatic COVID-19 infection 3 months ago and a history of chronic analgesic consumption for migraine. She was diagnosed as having AIH through extensive clinical and laboratory workup. This case may be an immediate enhancement of a hidden autoimmune disorder triggered by the vaccination. This adverse event following immunisation has an adequate temporal relationship with her COVID-19 vaccine. The causality can be categorised as ‘indeterminate’ and may be considered as a potential signal following COVID-19 vaccination.
Keywords: Open access, COVID-19
PubDate: 2023-08-23T00:45:27-07:00
DOI: 10.1136/ejhpharm-2022-003485
Issue No: Vol. 30, No. 5 (2023)
- Acute kidney injury and delayed methotrexate clearance in an adult patient
with Philadelphia chromosome-positive acute lymphoblastic leukaemia
treated with imatinib-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Chen, C; Qi, J, Li, X, Yongjing, W.
Pages: e28 - e28
Abstract: A female patient in her early 30s was treated with imatinib and high-dose methotrexate (HD-MTX) for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The patient developed delayed MTX clearance and grade 3 acute kidney injury characterised by elevated creatinine (114% increase from baseline). After intensified calcium folinate rescue therapy and hydration, the MTX serum level was appropriately decreased 72 hours after the start of MTX infusion, and renal function returned to normal. Medication analysis by a clinical pharmacist suggested that the concomitant treatment with imatinib likely contributed to the delayed MTX clearance and caused the acute kidney injury.
PubDate: 2023-08-23T00:45:27-07:00
DOI: 10.1136/ejhpharm-2022-003453
Issue No: Vol. 30, No. 5 (2023)
- The geriatric clinical pharmacist at the emergency department: a novel
front-door transdisciplinary care model-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Cheong, T. S; Zhu, B, Chong, E.
Pages: e29 - e29
PubDate: 2023-08-23T00:45:27-07:00
DOI: 10.1136/ejhpharm-2022-003458
Issue No: Vol. 30, No. 5 (2023)
- Dl-3-n-butylphthalide induced anaphylactic shock: a case report
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Huang, W; Cao, L, Ding, L, He, X.
Pages: e23 - e23
Abstract: Dl-3-n-butylphthalide (DL-NBP) has good neuroprotective function and is safe for use in patients with acute ischaemic stroke. DL-NBP induced anaphylactic shock is rarely reported. Here we describe the case of a 75-year-old woman who received an injection of DL-NBP (25 mg/100 mL intravenously guttae, twice daily) for acute ischaemic stroke. Approximately 5 min after the DL-NBP injection was administered, the patient developed a decrease in blood pressure and an increase in heart rate along with skin pruritus, mottlement of the lower limbs, discomfort, and the desire to defecate, following which DL-NBP was discontinued immediately. The patient recovered with antiallergic therapy and could tolerate further treatment. We emphasise that the increased use of DL-NBP in recent year raises the importance of attention to potential allergies in clinical use, especially in patients with a history of allergies to multiple drugs.
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-003124
Issue No: Vol. 30, No. 5 (2023)
- Pancytopenia in a patient treated with fusidic acid and niraparib: a case
report-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Damerval, M; Bazan, F, Omrani, S, Hugues, M, Roux, M.-F, Mayer, J.
Pages: e24 - e24
Abstract: Fusidic acid is an antibiotic used in the treatment of staphylococcal infections. Niraparib is an anticancer drug indicated for the treatment of advanced ovarian cancer. The interaction between these two drugs has not been studied and is not referenced in drug databases. We present the case of a patient with pancytopenia who had been treated with fusidic acid and niraparib. No other treatment was taken by this patient. According to the literature, both substances can cause haematological toxicity. It seems unlikely that this is due to niraparib alone because it had been well tolerated by the patient for over a year before the pancytopenia was diagnosed. It was also perfectly well tolerated when it was reintroduced. We cannot determine whether this pancytopenia is due to fusidic acid alone or to a drug interaction between the two treatments. We therefore recommend caution in patients treated with this combination.
Keywords: Open access
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002819
Issue No: Vol. 30, No. 5 (2023)
- Choose carefully where to publish your research
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Wiffen; P.
Pages: 249 - 249
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2023-003927
Issue No: Vol. 30, No. 5 (2023)
- Medication-related problems in critical care survivors: a systematic
review-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Short, A; McPeake, J, Andonovic, M, McFee, S, Quasim, T, Leyland, A, Shaw, M, Iwashyna, T, MacTavish, P.
Pages: 250 - 256
Abstract: ObjectivesThere are numerous, often single centre discussions of assorted medication-related problems after hospital discharge in patients who survive critical illness. However, there has been little synthesis of the incidence of medication-related problems, the classes of medications most often studied, the factors that are associated with greater patient risk of such problems or interventions that can prevent them.MethodsWe undertook a systematic review to understand medication management and medication problems in critical care survivors in the hospital discharge period. We searched OVID Medline, Embase, PsychINFO, CINAHL and the Cochrane database (2001–2022). Two reviewers independently screened publications to identify studies that examined medication management at hospital discharge or thereafter in critical care survivors. We included randomised and non-randomised studies. We extracted data independently and in duplicate. Data extracted included medication type, medication-related problems and frequency of medication issues, alongside demographics such as study setting. Cohort study quality was assessed using the Newcastle Ottowa Score checklist. Data were analysed across medication categories.ResultsThe database search initially retrieved 1180 studies; following the removal of duplicates and studies which did not fit the inclusion criteria, 47 papers were included. The quality of studies included varied. The outcomes measured and the timepoints at which data were captured also varied, which impacted the quality of data synthesis. Across the studies included, we found that as many as 80% of critically ill patients experienced medication-related problems in the posthospital discharge period. These issues included inappropriate continuation of newly prescribed drugs such as antipsychotics, gastrointestinal prophylaxis and analgesic medications, as well as inappropriate discontinuation of chronic disease medications, such as secondary prevention cardiac drugs.ConclusionsFollowing critical illness, a high proportion of patients experience problems with their medications. These changes were present across multiple health systems. Further research is required to understand optimal medicine management across the full recovery trajectory of critical illness.PROSPERO registration numberCRD42021255975.
Keywords: EAHP Statement 5: Patient Safety and Quality Assurance
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2023-003715
Issue No: Vol. 30, No. 5 (2023)
- Access to medicines
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Miljkovic, N; Makridaki, D, Kohl, S.
Pages: 257 - 260
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002974
Issue No: Vol. 30, No. 5 (2023)
- Hazardous medicinal products
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Batista, A; Makridaki, D, van der Schors, T, Kohl, S, delegates of the 52nd EAHP General Assembly
Pages: 261 - 263
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2022-003472
Issue No: Vol. 30, No. 5 (2023)
- Effectiveness of antithrombotic prophylaxis in hospitalised patients with
SARS-CoV-2 infection-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Quiros Ambel, H; Crespo-Robledo, P, Arribalzaga Juaristi, K, Plo-Seco, I, Martinez Simon, J. J, Perez Fernandez, E, Perez Encinas, M.
Pages: 264 - 267
Abstract: BackgroundAntithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 acute infection has increased. Currently, most of the evidence relates to patients in intensive care units; however, there is little information on patients admitted to hospital wards and there is no consensus protocol on thromboprophylaxis during admission and after discharge.ObjectiveTo assess the effectiveness of antithrombotic prophylaxis in patients admitted with COVID-19 and 30 days after discharge.MethodA prospective observational study was conducted of patients admitted with COVID-19 in which the hospital thromboprophylaxis protocol was applied, classifying the patients as having a standard or high risk of thrombosis. Pharmacists performed a daily follow-up and actively intervened during admission and at discharge. The main outcome measure was the global incidence of symptomatic venous thromboembolism (VTE) related to hospitalisation.ResultsA total of 113 patients were included, 98.23% of whom were admitted to a hospital ward. The incidence of hospital-acquired VTE was 1.77%. In 75.22% of the subjects, thromboprophylaxis was adjusted to the protocol during admission. A total of 23 pharmaceutical interventions were conducted, with an adherence of 52.17%. At discharge, 94.28% of the patients who had no haemorrhage and ≥4 points on the Padua Prediction Score required thromboprophylaxis, aligning with the protocol. The global incidence of haemorrhagic events during the follow-up period was 0.88%.ConclusionThe incidence of hospital-acquired VTE was lower than that described in the literature. Although it cannot be certain that it is directly related to the instituted protocol, the data can show that the management of prevention of VTE is being optimally performed at the hospital. Long-term studies are needed to evaluate the incidence after discharge, as well as to agree on a specific protocol in the COVID-19 population for the prevention of these events during hospitalisation and post-discharge.
Keywords: EAHP Statement 4: Clinical Pharmacy Services, COVID-19
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002877
Issue No: Vol. 30, No. 5 (2023)
- Real-world outcomes of abiraterone and enzalutamide in first-line
treatment of metastatic castration-resistant prostate cancer: which
patients benefit most'-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Garcia Trevijano Cabetas, M; Escario-Gomez, M, Gonzalez-Del Valle, L, Sobrino Jimenez, C, Bilbao Gomez-Martino, C, Romero-Garrido, J. A, Benedi-Gonzalez, J, Espinosa Arranz, E, Diaz Almiron, M, Herrero Ambrosio, A.
Pages: 268 - 272
Abstract: ObjectivesAbiraterone and enzalutamide are two oral novel androgen receptor axis-targeted agents approved for the treatment of castration-resistant prostate cancer (mCRPC). Despite the availability of multiple treatments, there is a need to improve the knowledge and management of these drugs in the real-world setting, especially in patient groups under-represented in clinical trials. Our aim was to review the outcome of patients with chemotherapy-naïve mCRPC treated with abiraterone or enzalutamide in routine clinical practice in order to identify factors that are predictive for response.MethodsThis observational retrospective study was performed in a Spanish tertiary hospital and included men with chemotherapy-naïve mCPRC who started treatment with abiraterone or enzalutamide between September 2012 and November 2018. The study end date was 30 October 2020.ResultsNinety patients with mCRPC were included, 57 with abiraterone and 33 with enzalutamide. Median overall survival (OS) was 26.87 months (95% CI 19.68 to 34.05), with no difference found between the two treatment groups. Nine variables were related to increased OS in the univariate analysis: Eastern Cooperative Oncology Group (ECOG) performance status (0–1 vs 2), pain (need of opioids for cancer pain), visceral disease, ≥3 bone lesions, exclusively lymph node metastases, baseline prostate specific antigen (PSA) (
Keywords: EAHP Statement 1: Introductory Statements and Governance
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002798
Issue No: Vol. 30, No. 5 (2023)
- Implementation and effectiveness of pharmacist-led interviews at patient
hospital admission in a rheumatology department-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Yailian, A.-L; Biry, L, Fontana, A, Vignot, E, Estublier, C, Confavreux, C, Pivot, C, Chapurlat, R, de Freminville, H, Janoly-Dumenil, A.
Pages: 273 - 278
Abstract: ObjectivesMedication reconciliation is time-consuming and its complete deployment can be difficult. The implementation of a simplified process, such as patient interviews at admission without full reconciliation, may contribute to improve patient care. The objective of the present study was to describe the feasibility and assess the potential effectiveness of implementing pharmacist-led interviews at patient admission to a rheumatology department.MethodsThis is a prospective observational study of pharmacist-led interviews at patient admission conducted between April 2015 and May 2017 in the 34-bed rheumatology department of Edouard Herriot Hospital, a French university hospital. These interviews were structured to explore patient medication management at home. The main outcome was the number of medication errors at admission. Other outcomes were the total number of interviews, the number of interviews with at least one new item of information provided by the patient, the number of interviews with at least one medication error detected, and the number of interviews leading to a modification of the hospital medication order.ResultsA total of 247 interviews were carried out; there was an increase in the number of interviews over the study period (n=54 in 2015, n=98 in 2016, and n=95 for the first 5 months of 2017). Among the interviews conducted, 135 (55%) provided new information concerning patient medication management and 117 medication errors were identified in hospital orders (0.47/patient). There were 76 interviews (31%) with at least one medication error; all led to a medication order modification.ConclusionsThe study found that pharmacist-led interviews at patient admission were effective in detecting medication errors. They could be an alternative to a full medication reconciliation process in targeted situations. When the patient interview does not provide sufficiently robust information, full medication reconciliation may be performed.
Keywords: EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002786
Issue No: Vol. 30, No. 5 (2023)
- Self-administration of medications in inpatient postnatal women: an
opportunity to empower self-care, improved medicines knowledge and
adherence utilising clinical pharmacists and midwifery workforce and use
of a midwife formulary-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Wright, S. A; Higgins, C, Carson, J, Kinnear, M, Smith, P, Mary, N, Westall, E, Arshad, S.
Pages: 279 - 283
Abstract: ObjectivesTo assess the impact of self-administration of medicines (facilitated by a midwife formulary) on postnatal women’s knowledge of certain post-delivery medications, awareness of the Green Bag Scheme, factors contributing to constipation, pain satisfaction, adherence, and time released to midwives plus feedback from these women and their midwives.MethodsThe study was conducted in consented postnatal women, who self-administered medications from their bedside lockers. The mode of delivery and parity were recorded. Data were compared in women who self-administered to those who did not. Midwives used our established midwife formulary to write their essential unprescribed medications. Direct interview questionnaires were used to obtain their knowledge on chosen post-delivery medicines, pain satisfaction, the Green Bag Scheme and factors contributing to constipation. Regular medicines counts were used to check adherence. Midwives’ time not administering these self-administered medications was estimated. Self-reported questionnaires were used to obtain feedback from participants and midwives. Responses were analysed proportionately and where appropriate by simple statistics.ResultsWomen (n=203) who self-administered were compared with those (n=401) who did not. Greater medicines’ knowledge and better (96% vs 79%) pain satisfaction were found in self-administering women. Knowledge of each contributing factor to constipation varied. Mode of delivery and parity had no impact on these outcomes. Adherence seemed high 96% (195/203). Awareness of the Green Bag Scheme was poor (66/604). Most women, 94% (191/203) found the service helpful and 89% (178/200) would take part again. At least 224 hours were released to midwives by these self-administering women. 164/203 (81%) midwives felt the scheme was beneficial.ConclusionsSelf-administering women had better pain satisfaction, medication knowledge and adherence. The need to improve engagement in the Green Bag Scheme was flagged. This service, supported by use of a midwife formulary, can release time to midwives to do other tasks including care for women with more complex issues. A business case for this service is under review.
Keywords: Editor''s choice, EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002903
Issue No: Vol. 30, No. 5 (2023)
- Benefits of using a microencapsulated vitamin D delivery system in women
with polycystic ovary syndrome-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Yanachkova, V; Staynova, R, Stoev, S, Naseva, E.
Pages: 284 - 287
Abstract: ObjectiveTo compare and assess the efficacy of two vitamin D delivery systems (oil-based and microencapsulated) on 25-hydroxy-vitamin D (25(OH)D) levels, body mass index (BMI) and insulin resistance (IR) in women with established polycystic ovary syndrome (PCOS) and vitamin D deficiency.Materials and methodsA monocentric, retrospective study was conducted, using the data of 70 female patients, who visited the endocrinology department of the "Dr. Shterev" Hospital, Sofia, Bulgaria between May 2020 and September 2020. The patients were divided into two groups according to the type of vitamin D3 supplementation: either a microencapsulated liposomal form (n=35), or a conventional oil-based form (n=35). The following clinical measures were analysed and compared: BMI, serum levels of 25(OH)D, fasting plasma glucose levels, fasting immunoreactive insulin (IRI), homeostatic model assessment (HOMA) index, levels of antimullerian hormone (AMH) II generation, and testosterone. In all selected patients, these measurements were performed at baseline and 3 months after initiation of vitamin D supplementation.ResultsSignificantly increased serum levels of 25(OH)D were observed in patients supplemented with the microencapsulated form of vitamin D3 in the third month from the beginning of therapy, compared with the control group (p=0.003). In the microencapsulated vitamin D group, there was a decrease in IRI serum levels (p=0.023), HOMA-IR (p=0.021), serum AMH (p=0.010) and testosterone levels (p=0.006). The fasting plasma glucose levels did not change significantly.ConclusionThe results of our study show that the patients supplemented with a microencapsulated form of vitamin D3 achieved faster compensation of 25(OH)D levels, which in turn, under equal conditions, led to significant improvement in the metabolic profile, in particular insulin sensitivity.
Keywords: EAHP Statement 4: Clinical Pharmacy Services, EAHP Statement 5: Patient Safety and Quality Assurance
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002967
Issue No: Vol. 30, No. 5 (2023)
- Medicines Delivery Proximity Programme (PEMProxi) survey results
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Silva, S; Abreu, M, Dinis, A. P, Garcia, R, Rodrigues, M, Sequeira, C, Feio, J.
Pages: 288 - 292
Abstract: ObjectivesTo evaluate patients’ and community pharmacies’ satisfaction towards the Medicines Delivery Proximity Programme (PEMProxi), including patients’ level of satisfaction with pharmaceutical services, medication dispensing and delivery, cost, and time saved, community pharmacies’ satisfaction with PEMProxi-related information and procedures, contact with the patients, and timings. Additionally, to evaluate patients’ and community pharmacies’ perception of PEMProxi’s advantages and disadvantages.MethodsPatients and the community pharmacies included in PEMProxi were contacted by telephone to answer a survey. The patient survey included questions regarding their satisfaction level towards PEMProxi, medication dispensing and delivery, and cost and time saved. Patients were also asked to point out the advantages and disadvantages of PEMProxi and give improvement suggestions. The community pharmacy survey included questions regarding satisfaction with entering PEMProxi, related information, procedures, contact with the patients on PEMProxi, and timings. Programme-related advantages, disadvantages and improvement suggestions were also solicited.ResultsA total of 101 patients and 49 community pharmacies were included in the analysis. A large majority of patients were very satisfied with PEMProxi (93.1%). The Programme allowed each patient to save on average 30 and 8 hours per month. More than 95% of the patients reported medication delivery in adequate conditions (n=100), in a timely manner (n=95) and according to the prescription (n=95). Most pharmacies were satisfied or very satisfied with their participation in PEMProxi (63.3%). Nearly half (53.1%) were surprised by its implementation and 98% would be available to participate with more patients if the Programme was extended.ConclusionsThe PEMProxi programme contributed to more convenient and equitable access to medications by chronic patients, thus avoiding unnecessary trips to the hospital, saving them precious time and money.
Keywords: EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002893
Issue No: Vol. 30, No. 5 (2023)
- Design and validation of a predictive equation to estimate unbound
valproic acid concentration-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Conde Giner, S; Belles Medall, M. D, Ferrando Piqueres, R.
Pages: 293 - 296
Abstract: ObjectivesTotal plasma levels of valproic acid (VPA) may mask an increased risk of adverse effects in hypoalbuminaemic patients since, in these patients, the free fraction is higher. The aim of this study is to analyse the relationship between plasma levels of total and free VPA (FVPA) in hypoalbuminaemic patients and define an equation that allows the estimation of FVPA concentration, as well as to validate the obtained equation.MethodsThis is a retrospective observational study conducted between January 2015 and January 2020. Hypoalbuminaemic adult patients with normal renal function were included. Serum VPA levels were determined using an automated enzyme immunoassay technique with a pre-treatment of the sample by ultrafiltration for the quantification of FVPA. Patients’ determinations were randomised into two groups: first, to calculate the FVPA estimation equation (regression group) by multiple linear regression analysis; and second to validate the equation (validation group), calculating the agreement between experimental and estimated FVPA concentrations using Lin’s coefficient and a Bland and Altman analysis.ResultsWe included 51 determinations, corresponding to 33 patients: 26 in the regression group, and 25 in the validation group. The multiple linear regression analysis showed a statistically significant relationship between FVPA concentration (Y), total VPA concentration (X1) and albumin level (X2), explained by the equation Y=11.882 + 0.216*X1–4.722*X2. Pearson’s correlation coefficient was 0.798 (p
Keywords: EAHP Statement 4: Clinical Pharmacy Services
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-003092
Issue No: Vol. 30, No. 5 (2023)
- Medicine shortages in France: a 6-year retrospective study in a university
medical centre-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Traore, S. C; Decoene, A, Mazaud, P.
Pages: 297 - 301
Abstract: ObjectivesMedicine procurement disorders, commonly referred to as ‘shortages’, are a health-threatening phenomenon that have been reported by several stakeholders around the world. This study aimed to describe data from a mitigation tool, namely a shortages report implemented within one of the largest university hospitals in France over a 6-year period.MethodsFor 6 years (from 1 June 2014 to 31 May 2020) the data used were collected from different sources: purchasing groups, distributors, manufacturers and the national health agency. The report included: medicine identification, disorder duration, starting and ending dates, available alternative products, the Anatomical Therapeutic and Chemical (ATC) classification. Different situations were described: medicine shortages, quotas, supply tensions and market withdrawals.ResultsOver the 6-year period, 1780 disorders were registered comprising 0.67% market withdrawals, 16.97% quotas, 79.89% shortages and 2.47% supply tensions. The median duration of a disorder was 56 days and the most affected ATC classes were the nervous system (N), anti-infectives (J) and the cardiovascular system (C). A substitute medicine was registered for one-third of the disorders. In the N class, the most frequent level 4 classes were N01BB (local anaesthetic amids such as lidocaine, levobupivacaine and ropivacaine), N03AX (other antiepileptics) and N05AX (other antipsychotics). In the J class, the most frequent level 4 classes were J01CR (penicillin combinations), J01CA (extended-spectrum penicillins such as piperacillin and amoxicillin) and J01XX (other antibiotics for systematic use).ConclusionsProcurement disorders are still spreading. The study results are similar to those of other research teams around the world. Common answers have to be found to deal with the phenomenon, that include standardisation and risk assessment methods.
Keywords: EAHP Statement 2: Selection, Procurement and Distribution
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2021-002911
Issue No: Vol. 30, No. 5 (2023)
- Rhabdomyolysis in a male adolescent associated with monotherapy of
fluvoxamine-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Zhang, F; Gong, W, Cui, Z, Li, J, Lu, Y.
Pages: 302 - 304
Abstract: Rhabdomyolysis is a syndrome resulting from striated muscular breakdown, which may occur due to drug therapy with agents such as selective serotonin reuptake inhibitors (SSRIs). Although studies have shown that fluvoxamine can rarely cause myalgia, there are no reported cases of rhabdomyolysis due to fluvoxamine monotherapy. Here we describe a case of rhabdomyolysis due to fluvoxamine monotherapy for obsessive-compulsive disorder. The young adolescent developed pain in the extremities, and an increase in serum creatine kinase (CK) and myoglobin during fluvoxamine treatment. These adverse reactions were reversed immediately after the medicine was changed to another SSRI—sertraline. This is the first reported case of fluvoxamine-associated rhabdomyolysis. It is advisable to determine serum CK levels before starting fluvoxamine treatment, and then at regular intervals, to avoid the occurrence of severe acute kidney injury with possible life-threatening complications.
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2022-003533
Issue No: Vol. 30, No. 5 (2023)
- EAHPs special interest group on hospital pharmacists preparedness for
in-vivo GTMP publishes report-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Teixeira Pereira; D.
Pages: 305 - 306
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2023-003941
Issue No: Vol. 30, No. 5 (2023)
- Spain takes over Presidency of the Council of the European Union
-
Free pre-print version: Loading...
Rate this result:
What is this?
Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:
Teixeira Pereira; D.
Pages: 307 - 308
PubDate: 2023-08-23T00:45:26-07:00
DOI: 10.1136/ejhpharm-2023-003942
Issue No: Vol. 30, No. 5 (2023)
|
Hybrid journal (It can contain Open Access articles)
